Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.
ASTMH nominated Professor Rose McGready, SMRU Deputy Director, as an Honorary International Fellow. Rose received the prestigious award in recognition of outstanding accomplishment by an “individual not an American citizen who has made eminent contributions to some phase of tropical medicine and hygiene”. Rose will formally receive her award at the ASTMH Annual Meeting, to be help 28 Oct-1 Nov in New Orleans, Louisiana.
In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.
Current recommended treatment regimens for the most widely used medicine for uncomplicated Plasmodium falciparum malaria may be sub-optimal for small children and pregnant women according to a study led by Professor Joel Tarning.
8 June Bangkok (Thailand) – One of the world’s most widely used anti-malarial drugs is safe to use, say researchers, after a thorough review and analysis of nearly 200,000 malaria patients who’d taken the drug dihydroartemisinin-piperaquine (DHA-PPQ). There is such a low risk of sudden unexpected death from DHA-PPQ, one of the world’s most effective medicines to treat malaria, that there is no need to limit its current use, the researchers say ...
Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.
Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.
Primaquine can be used to prevent the transmission of falciparum malaria from human to mosquito. Bob Taylor and colleagues developped an age-based regimen for single low-dose primaquine to block the transmission of malaria in sub-Saharan Africa.
Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.
On 10 May 2018, SMRU Deputy Director Rose McGready was awarded the Alumni Award for Service to Humanity by the University of Sydney. The Alumni Award recognizes the personal contribution of alumni who, through service to philanthropy, improve the lives of those in need. It also seeks to recognize the significant involvement of Sydney alumni in projects that enrich local or international communities. In in her acceptance speech, Rose thanked the ...